home / openregs / legislation

legislation: 113-hr-5587

Congressional bills and resolutions from Congress.gov, filtered to policy areas relevant to environmental, health, agriculture, and wildlife regulation.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

bill_id congress bill_type bill_number title policy_area introduced_date latest_action_date latest_action_text origin_chamber sponsor_name sponsor_state sponsor_party sponsor_bioguide_id cosponsor_count summary_text update_date url
113-hr-5587 113 hr 5587 Opioid Abuse Prevention and Treatment Act of 2014 Health 2014-09-18 2014-09-19 Referred to the Subcommittee on Health. House Rep. Foster, Bill [D-IL-11] IL D F000454 5 Opioid Abuse Prevention and Treatment Act of 2014 - Requires the Secretary of Health and Human Services (HHS) to award grants to states to develop a peer review process to identify and investigate questionable or inappropriate prescribing and dispensing patterns of drugs classified as schedule II or III under the Controlled Substances Act, which are drugs with an accepted medical use that have the potential to be abused and addictive. Amends the Public Health Service Act to require the Secretary to establish grant programs to: (1) facilitate training to increase the capacity of health care providers to screen and treat patients to prevent drug abuse, and (2) develop continuing education criteria that allow health profession boards or state agencies to certify appropriate education for safe prescribing of schedule II or III drugs. Requires the Administrator of the Health Resources and Services Administration to award grants to evaluate the prospect of state health professions boards expanding the authority of providers to prescribe drugs to treat drug abuse. Requires the Attorney General to request that practitioners registered to dispense controlled substances screen patients for potential drug abuse before prescribing a schedule II or III drug. Directs the Food and Drug Administration (FDA) to consider whether naloxone (a prescription drug used to rapidly reverse an overdose of heroin or other opioids, which are drugs with effects similar to opium) should be available without a prescription. Requires the Secretary to use an interagency working group to encourage states and local governments to increase opportunities for disposal of opiates (drugs derived from opium) and to reduce opportunities for abuse of opiates. Requires the Government Accountability Office (GAO) to review federal opioid abuse activities and make recommendations to reduce opioid abuse and overdoses. 2023-01-11T13:25:33Z  

Links from other tables

  • 4 rows from bill_id in legislation_actions
  • 18 rows from bill_id in legislation_subjects
  • 5 rows from bill_id in legislation_cosponsors
  • 0 rows from bill_id in cbo_cost_estimates
Powered by Datasette · Queries took 0.899ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API